Emcure Pharmaceuticals announced that its members have approved the re-appointment of three key Independent Directors through a remote e-voting process concluded on March 20, 2026. Mr. Vijay Keshav Gokhale and Dr. Vidya Rajiv Yeravdekar secured a second term of 5 and 3 years, respectively, starting April 16, 2026. Dr. Shailesh Kripalu Ayyangar was also re-appointed for a second term of 5 years, effective June 02, 2026.
Shareholder Approval for Director Re-appointment
Emcure Pharmaceuticals Limited has formally disclosed the successful conclusion of its shareholder voting process concerning the reappointment of several Independent Directors. The approval was secured via a Postal Ballot conducted through remote e-voting, which finalized on March 20, 2026. The results were announced on March 24, 2026, based on the Scrutinizer’s report dated March 23, 2026.
Details of Re-appointed Directors and Terms
The following directors received member approval for their continuation in their roles:
- Mr. Vijay Keshav Gokhale (DIN: 09134089) has been approved for a second term of 5 (five) consecutive years, effective from April 16, 2026.
- Dr. Vidya Rajiv Yeravdekar (DIN: 02183179) has been approved for a second term of 3 (three) consecutive years, also effective from April 16, 2026.
- Dr. Shailesh Kripalu Ayyangar (DIN: 00268076) has been approved for a second term of 5 (five) consecutive years, commencing on June 02, 2026.
Compliance and Declarations
The company confirmed that all three directors—Mr. Vijay Keshav Gokhale, Dr. Vidya Rajiv Yeravdekar, and Dr. Shailesh Kripalu Ayyangar—are not barred from holding directorial office by any regulatory order. Furthermore, they confirmed they hold no disqualifying relationship with any other existing Director or Key Managerial Personnel of the Company.
The necessary disclosure particulars, as required under the relevant listing regulations, have been enclosed with the official intimation dated March 24, 2026.
Source: BSE
